Valiltramiprosate/ALZ‐801 Prevents Hippocampal Atrophy and Clinical Decline in a Stage 2 AD Subpopulation in APOLLOE4 Phase 3 Study
Valiltramiprosate demonstrates potential for preventing hippocampal atrophy and stabilization of cognitive and functional decline in earliest symptomatic APOE4/4 AD. The results support a potential disease stabilization benefit of oral valiltramiprosate as a prevention therapy in presymptomatic AD.
Authors
- John A. Hey (ORCID: https://orcid.org/0000-0002-5104-6231)
- Shaina M. Short (ORCID: https://orcid.org/0000-0002-2516-703X)
- Jean F. Schaefer
- Martin Tolar (ORCID: https://orcid.org/0000-0002-3910-091X)
- Hugo Geerts
- Aidan Power
- Susan Abushakra
- Jeremy Yu
Institutions
- GP Technologies (United States) (US)
- Predictive Science (United States) (US)
- Framingham State University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108565
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00